Accurate distinguishing HER2‐low breast cancers is particularly critical, as HER2‐low patients have now emerged as a distinct therapeutic subgroup eligible for novel ADCs treatments.[24] HER2‐zero patients generally do not benefit from HER2‐targeted therapies. This evidence concerns the gene ERBB2 and breast carcinoma.